Why oil-price rallies soon falter

Opec, the oil exporters’ cartel, has never been very good at sticking to deals to rein in output and prop up the oil price.

Opec, the oil exporters' cartel, has never been very good at sticking to deals to rein in output. They recently agreed to cut production to mop up a glut and shore up prices, but it turns out they aren't doing too well this time round either. According to the International Energy Agency, some producers are "showing signs of weakening their resolve".

In July, the compliance rate among Opec members was just 75%; overall production actually rose. Expect the cheating to continue, Tariq Zahir of Tyche Capital Advisors told Barron's.com. Some countries could even pull out of the deal altogether.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

US shale is coping with lower and lower prices, producing more oil and thus capping price rallies, just as Opec has begun to need the highest oil price of anyone in the market higher than Big Oil too. The US government estimates that American production will hit an all-time high in 2018, eclipsing 1970's figure. No wonder oil-price rallies never last very long.

Andrew Van Sickle
Editor, MoneyWeek

Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.

After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.

His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.

Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.